We are a globally operating Contract Development and Manufacturing Organisation (CDMO) headquartered in Germany. Our three production sites in Germany, France, and Japan focus on the production of FDF in the small-molecule segment. The sites cover relevant technologies in sterile liquids, non-sterile liquids, and semi-solids, providing end-to-end services for our large base of pharma customers.
Location: Germany, Bavaria, Munich
Employees: 201-500
Founded date: 2020
Investors 1
| Date | Name | Website |
| 12.02.2022 | FSN Capita... | fsncapital... |
Mentions in press and media 6
| Date | Title | Description |
| 20.03.2023 | Adragos Pharma acquires Clinigen's development unit, Lamda Laboratories | Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment Agreement includes further product development activities for Clinigen Limited Lamda spurs further growth for Adrag... |
| 02.03.2023 | Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan | Adragos Pharma now third largest pure-play CDMO in the Japanese market Long-term agreement with Sanofi secures local healthcare supply Munich / Paris / Tokyo, March 02, 2023 – Munich-based pharmaceutical contract manufacturer (CDMO) Adragos... |
| 13.10.2022 | Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan | Munich / Paris / Tokyo, October 13, 2022 – Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi K.K. for the acquisiti... |
| 10.08.2021 | The U.S. venture capital world is blistering hot. Why it won’t cool down just yet | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Paid Content The art of swapping cars—for art From Polestar Good morning, Term Sheet readers. Fin... |
| 10.08.2021 | The U.S. venture capital world is blistering hot. Why it won’t cool down just yet | Good morning, Term Sheet readers. Finance reporter Anne Sraders here again, filling in for Lucinda. If one thing’s for sure, it’s been a record-breaking year in the venture capital space—whether you’re talking fundraising or mega deals. Loo... |
| 09.08.2021 | FSN Capital VI partners with Prange Group to accelerate growth of rising CDMO Adragos Pharma | Munich/Plettenberg, August 9th, 2021 FSN Capital VI* (“FSNC”) has acquired a majority share in Adragos Pharma Group (“Adragos”), a growing B2B contract developer and manufacturer (CDMO) for pharmaceuticals. The current owner, Prange Group ... |